TrkA 

 74 Products   74 Products   309 Diseases   14447 News 


12345678910111213...169170»
  • ||||||||||  Opdivo (nivolumab) / BMS, Cabometyx (cabozantinib tablet) / Exelixis
    Journal, PD(L)-1 Biomarker, IO biomarker:  Clinical observation of nivolumab combined with cabozantinib in the treatment of advanced hepatocellular carcinoma. (Pubmed Central) -  Apr 16, 2025   
    Altogether, this approach demonstrates significant potential in improving biomarker discovery and guiding personalized treatments. When treating advanced HCC, nivolumab and cabozantinib together have the ability to increase T lymphocyte numbers, reduce tumor marker levels, effectively prolong survival time, and have better efficacy than simple control treatment, with good safety.
  • ||||||||||  Cometriq (cabozantinib capsule) / Exelixis, Koselugo (selumetinib) / Merck (MSD), AstraZeneca, Cabometyx (cabozantinib tablet) / Exelixis
    Trial completion date, Trial initiation date, Trial primary completion date:  NF113: Study of Cabozantinib With Selumetinib for Plexiform Neurofibromas (clinicaltrials.gov) -  Apr 16, 2025   
    P1,  N=30, Not yet recruiting, 
    When treating advanced HCC, nivolumab and cabozantinib together have the ability to increase T lymphocyte numbers, reduce tumor marker levels, effectively prolong survival time, and have better efficacy than simple control treatment, with good safety. Trial completion date: Apr 2033 --> Jul 2033 | Initiation date: Apr 2025 --> Jul 2025 | Trial primary completion date: Apr 2032 --> Jul 2032
  • ||||||||||  Review, Journal:  Recent Advances in Succinate Dehydrogenase Deficient Gastrointestinal Stromal Tumor Systemic Therapies. (Pubmed Central) -  Apr 11, 2025   
    Additional research into TKI agents with anti-vascular endothelial growth factor receptor (VEGFR) and anti-fibroblast growth factor receptor (FGFR) activity in this clinical setting is needed. Patients with SDH-Def will benefit more broadly from ongoing explorations of treatments with alternative mechanisms of action, especially those that exploit cellular pathways involved in SDH-Def GIST tumorigenesis.
  • ||||||||||  Stivarga (regorafenib) / Bayer
    Journal:  A PD-L1/CD3 BISPECIFIC ANTIBODY ENHANCES THE ANTI-TUMOR EFFECTS OF REGORAFENIB AGAINST COLON CANCER. (Pubmed Central) -  Apr 9, 2025   
    Therefore, the immunomodulatory benefits of REG can be effectively paired with a bsAb that anchors to CRC cells, diminishes immunosuppression (through PD-L1 blockade), and activates/sustains antigen-specific CD8+ T cells within the TME. Our newly described REG + bsAb regimen led to improved anti-tumor outcomes pre-clinically and may represent a promising future approach for CRC patients.
  • ||||||||||  Lonsurf (trifluridine/tipiracil) / Otsuka, Stivarga (regorafenib) / Bayer
    Review, Journal:  Managing adherence, exposure, and toxicity in oral anticancer therapies. (Pubmed Central) -  Apr 8, 2025   
    This review highlights key efforts to enhance adherence, reduce occupational exposure, and improve adverse effect management in OAA therapy.(1) Adherence management.We evaluated adherence to trifluridine/tipiracil hydrochloride (TFTD) in metastatic colorectal cancer (mCRC) patients, revealing an overall adherence rate of 85.0%...These findings emphasize the need for continuous safety training and enhanced spill management protocols.(3) Adverse effect management.We examined regorafenib-induced adverse effects, particularly hand-foot skin reaction (HFSR) and hypothyroidism...Early intervention and supportive care strategies improved treatment tolerability.This review underscores the importance of pharmacist-driven interventions in enhancing adherence, ensuring occupational safety, and managing adverse effects. Continued research and collaboration are essential to optimize OAA-based therapy and improve patient care in oncology pharmacy.
  • ||||||||||  Rozlytrek (entrectinib) / Roche, Keytruda (pembrolizumab) / Merck (MSD), Vitrakvi (larotrectinib) / Bayer
    Journal, Tumor mutational burden, MSi-H Biomarker, PD(L)-1 Biomarker:  Current management of neurotrophic receptor tyrosine kinase fusion-positive sarcoma: an updated review. (Pubmed Central) -  Apr 7, 2025   
    In recent years, pembrolizumab has demonstrated significant efficacy in treating tumors characterized by a high tumor mutational burden and high microsatellite instability...NTRK fusion genes are present in various cancer types, including sarcomas, and the TRK inhibitors larotrectinib and entrectinib have been effectively used for these malignancies...However, further research is warranted to optimize treatment duration and subsequent management strategies. The accumulation of clinical cases worldwide will play a pivotal role in refining the treatment approaches for tumors associated with NTRK fusion genes.
  • ||||||||||  Dovbleron (taletrectinib) / Nuvation Bio
    Journal:  Taletrectinib in ROS1+ Non-Small Cell Lung Cancer: TRUST. (Pubmed Central) -  Apr 3, 2025   
    The patient continued adjuvant entrectinib therapy and has remained recurrence-free during follow-up, with 21 Taletrectinib showed a high response rate with durable responses, robust IC activity, prolonged PFS, favorable safety, and low rates of neurologic adverse events in TKI-na
  • ||||||||||  Vitrakvi (larotrectinib) / Bayer
    Efficacy and safety of larotrectinib as first-line treatment for adult patients with TRK fusion cancer (Villa Ciani) -  Apr 3, 2025 - Abstract #SarcomaRC2025SARCOMA_RC_260;    
    P1, P1/2,
    Conclusions Laro demonstrates rapid and durable responses, extended survival and a favourable safety profile in adult pts without prior systemic therapy. This supports the use of laro in a first-line setting and the wider adoption of NGS panels that include NTRK gene fusions to identify adult pts who may benefit from targeted treatment.
  • ||||||||||  Qinlock (ripretinib) / Ono Pharma, Stivarga (regorafenib) / Bayer
    Optimizing second-line therapy for advanced gastrointestinal stromal tumors: Real-world efficacy and safety analysis (Villa Ciani) -  Apr 3, 2025 - Abstract #SarcomaRC2025SARCOMA_RC_258;    
    P
    Median PFS (mPFS) for ripretinib, sunitinib and regorafenib was 11.4, 12.4 and 2.8 months, respectively (p=0.296)...Conclusions Our preliminary results suggest that ripretinib may offer superior clinical benefits for patients with primary KIT exon 11 mutations after failure of imatinib first-line treatment...Editorial acknowledgement Legal entity responsible for the study The authors. Funding Has not received any funding.
  • ||||||||||  Vitrakvi (larotrectinib) / Bayer
    Treatment discontinuation outcomes in paediatric patients with TRK fusion sarcomas treated with larotrectinib (Hall A) -  Apr 3, 2025 - Abstract #SarcomaRC2025SARCOMA_RC_157;    
    P1/2
    Conclusions Laro demonstrated robust, durable responses and favourable safety in paediatric pts with TRK fusion sarcomas who had a drug holiday. Stopping treatment is feasible following surgical resection or durable response, with most pts benefitting clinically with laro resumption on disease progression.
  • ||||||||||  Retevmo (selpercatinib) / Eli Lilly, Gavreto (pralsetinib) / Rigel
    Review, Journal:  Treatment of non-small cell lung cancer with RET rearrangements. (Pubmed Central) -  Apr 2, 2025   
    Selpercatinib has shown superiority over chemotherapy in a phase 3 study (LIBRETTO-431) in previously untreated patients with RET fusion-positive NSCLC, which established its place as the standard of care in this patient population. This review discusses the biology and clinical characteristics of RET-rearranged NSCLC and summarizes the evolution of treatment strategies, current understanding of mechanisms of resistance, and development of new-generation agents to overcome resistance.
  • ||||||||||  Review, Journal:  Targeting ROS1 rearrangements in non-small cell lung cancer: Current insights and future directions. (Pubmed Central) -  Apr 2, 2025   
    First-generation inhibitors, such as crizotinib and entrectinib, have demonstrated impressive efficacy, with objective response rates exceeding 60%-70%...Next-generation TKIs, including lorlatinib, taletrectinib, and repotrectinib, have been developed to overcome these challenges...Zidesamtinib, a highly selective next-generation ROS1 inhibitor, further addresses TRK-mediated off-target neurological toxicities seen with prior agents, and is poised to offer improved tolerability...In addition, the development of novel diagnostic tools, including RNA-based next-generation sequencing, has enhanced the detection of functional ROS1 fusions by ensuring that patients with actionable mutations receive appropriate targeted therapies. These advances highlight the evolving landscape of treatment for ROS1-positive NSCLC, with the aim of maximizing long-term survival and quality of life.